Can Airflow Limitation in Chronic Obstructive Pulmonary Disease (COPD) be Reversible by Drugs?

NCT ID: NCT01010178

Last Updated: 2009-11-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-02-29

Study Completion Date

2009-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Critical combination of various approved drugs in management for patients suffering with COPD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Macrolid, Theophylline, Corticosteroids

Approved drug in this setting

Group Type EXPERIMENTAL

Macrolid, Theophylline, Inhaler Corticosteroids

Intervention Type DRUG

we have no permission to include them in detail because of privacy policy of mentioned journal for publication

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Macrolid, Theophylline, Inhaler Corticosteroids

we have no permission to include them in detail because of privacy policy of mentioned journal for publication

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* current or past smoker COPD

Exclusion Criteria

* history of significant occupational or other environmental exposures or a connective tissue disease
Minimum Eligible Age

22 Years

Maximum Eligible Age

86 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Baqiyatallah Medical Sciences University

OTHER

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Center of Chemical Injuries, Baqiyatallah Medical Sciences University, Mollasadra St,

Tehran, , Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BMT-1388-2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Change of Inspiratory Peak Flow in COPD
NCT00561886 COMPLETED PHASE4